Invivyd (IVVD) Akcie Kurz

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2021-08-06. The company is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. The company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify antibodies with a barrier to viral escape. The company has a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including VYD222, a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5. VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.